Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F102 - Hand and Foot Psoriasis, Dermatitis and Other Inflammatory Dermatoses

Sunday, February 18; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify and diagnose common inflammatory hand and foot inflammatory dermatoses including psoriasis, irritant and allergic contact dermatitis and palmo-plantar pustulosis
  • Identify which patients with hand and foot inflammatory dermatoses should be patch tested and use the proper allergens and series
  • Use evidence-based data to select the best treatment options (including topical, phototherapy and systemic therapy) for hand and foot psoriasis, dermatitis and palmo-plantar pustulosis

Description

Common inflammatory dermatoses such as psoriasis, atopic dermatitis and contact dermatitis often involve hands and feet. Unfortunately, the morphology is often different on palms and soles making the diagnosis more challenging. Treatment of these inflammatory skin conditions is also more difficult when palms or soles are involved. This session will review the different clinical presentations of common hand and feet dermatoses and the role of patch testing. The focus will be on the management of hand and foot psoriasis, dermatitis and palmo-plantar pustulosis. Recent data on the efficacy of biological agents and oral systemic agents and will be reviewed and discussed.

Disclosures

  • Bissonnette, Robert, MD, MSc: AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Biopharmx – Independent Contractor(Fees); BioPharmX – O(Grants/Research Funding); BMS – A(Fees); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H), I(Grants/Research Funding); Cipher Pharmaceuticals – C(Fees), C(H); Dermira – I(H); Eli Lilly and Company – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding), SP(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding); Xenon Pharmaceuticals – I(H);
  • Cohen, David Eric, MD: Bickel Biotechnology – B(SO); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H); Allergan, Inc. – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana Biosciences, LLC – C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Dermira – A(H), C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding); Medimmune – A(H), C(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Stiefel a GSK company – C(H); Theravance Biopharma – C(H); Vitae Pharmaceuticals – C(H), I(Grants/Research Funding);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Almirall – C(H); Amgen – C(H), I(NC); Boehringer Ingelheim – C(H), I(NC); Bristol-Myers Squibb – C(Fees); Celgene Corporation – A(H), C(H), I(NC); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Galderma Research & Development, LLC – I(Grants/Research Funding); GlaxoSmithKline – C(H); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Medac Pharma, Inc – C(H); Meiji Seika Pharma Co., Ltd – C(Fees); Menlo Therapeutics – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Ortho Dermatologics – C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
Schedule
Sunday, February 18
1:00 PM
Dr. Bissonnette / Introduction and differential diagnosis
1:25 PM
Dr. Strober / Management of hand and foot psoriasis
1:50 PM
Dr. Guttman / Management of hand and foot dermatitis
2:15 PM
Dr. Cohen / Role of patch testing in patients with inflammatory hand and food dermatoses
2:40 PM
All faculty / Question period
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 30E
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Robert Bissonnette, MD, MSc, FAAD
Speakers
  • Bruce Elliot Strober, MD, PhD, FAAD
  • David Eric Cohen, MD, FAAD
  • Emma Guttman, MD, PhD, FAAD - Handout